Acumen Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Acumen PharmaceuticalsDer Gewinn des Unternehmens wird voraussichtlich um 11.5% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 87.2% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich sinken um 7.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -116.1% betragen.

Wichtige Informationen

-11.5%

Wachstumsrate der Gewinne

-7.1%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.4%
Wachstumsrate der Einnahmen	87.2%
Zukünftige Eigenkapitalrendite	-116.1%
Analystenabdeckung	Low
Zuletzt aktualisiert	13 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth

Sep 21

We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate

Feb 01

Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans

Oct 16

Acumen Pharma at 11-month high on rivals’ Alzheimer’s data

Sep 28

Acumen Pharmaceuticals initiated at buy at H.C. Wainwright on Alzheimer's candidate

Jun 30

We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth

May 10

We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate

Jan 07

Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans

Oct 01

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:ABOS - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	N/A	-121	-137	-141	3
12/31/2025	N/A	-119	-117	-120	4
12/31/2024	N/A	-95	-80	-80	4
9/30/2024	N/A	-82	-67	-67	N/A
6/30/2024	N/A	-65	-56	-56	N/A
3/31/2024	N/A	-56	-51	-51	N/A
12/31/2023	N/A	-52	-43	-43	N/A
9/30/2023	N/A	-49	-46	-46	N/A
6/30/2023	N/A	-46	-42	-42	N/A
3/31/2023	N/A	-45	-37	-37	N/A
12/31/2022	N/A	-43	-35	-35	N/A
9/30/2022	N/A	-38	-28	-28	N/A
6/30/2022	N/A	-32	-26	-26	N/A
3/31/2022	N/A	-83	-24	-24	N/A
12/31/2021	N/A	-101	-18	-18	N/A
9/30/2021	0	-93	-17	-17	N/A
6/30/2021	1	-92	-11	-11	N/A
3/31/2021	1	-32	-8	-8	N/A
12/31/2020	1	-7	-7	-7	N/A
12/31/2019	2	-8	-7	-7	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ABOS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ABOS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ABOS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ABOS wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: ABOS wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: ABOS wird voraussichtlich in 3 Jahren unrentabel sein.

Acumen Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 8.7% to US$10.80

Price target decreased by 8.4% to US$14.00

Price target increased by 8.6% to US$16.60

Price target decreased by 8.0% to US$14.57

Price target increased to US$17.20

Price target increased to US$16.00

Recent updates

Price target decreased by 8.7% to US$10.80

Acumen Pharmaceuticals, Inc. Appoints Amy Schacterle as Chief Regulatory Officer and Head of Quality

Acumen Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Does Acumen Pharmaceuticals (NASDAQ:ABOS) Have A Healthy Balance Sheet?

Acumen Pharmaceuticals, Inc. Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC) 2024

Acumen Pharmaceuticals: Healthy Cash Runway And Market Potential In Alzheimer's

Acumen Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 14, 2024

Acumen Pharmaceuticals, Inc., Annual General Meeting, Jun 04, 2024

Is Acumen Pharmaceuticals (NASDAQ:ABOS) Weighed On By Its Debt Load?

Acumen Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 26, 2024

Acumen Pharmaceuticals, Inc. Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's At the AD/PD 2024 Annual Meeting

Acumen Pharmaceuticals, Inc. Appoints James Doherty as Its President and Chief Development Officer

Price target decreased by 8.4% to US$14.00

CEO, President & Director notifies of intention to sell stock

Price target increased by 8.6% to US$16.60

Acumen Pharmaceuticals, Inc. announced that it expects to receive $50 million in funding

Acumen Pharmaceuticals, Inc. announced that it expects to receive $50 million in funding

Acumen Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Acumen Pharmaceuticals, Inc. Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen and Safety Findings for ACU193 in Early Alzheimer's Disease at the 16th Annual Clinical Trials on Alzheimer's Disease

Acumen Pharmaceuticals, Inc. to Present Deeper Insights from First-In-Human Phase 1 Study of ACU193 for Early Alzheimer’s During Symposium At the 16Th Annual Clinical Trials on Alzheimer’s Disease (CTAD)

Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth

Independent Director notifies of intention to sell stock

Acumen Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New minor risk - Shareholder dilution

Acumen Pharmaceuticals, Inc. Presents Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease at the Alzheimer’s Association International Conference (AAIC) 2023

Price target decreased by 8.0% to US$14.57

Acumen Pharmaceuticals Completes Enrollment in Phase 1 Trial of Acu193, First Monoclonal Antibody Developed to Selectively Target Toxic A<Beta> Oligomers in Patients with Early Alzheimer's Disease

Acumen Pharmaceuticals Provides Updates with Respect to INTERCEPT-AD

We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate

Acumen Pharmaceuticals Appoints Derrell Porter, M.D., to Its Board of Directors

Price target increased to US$17.20

Key Executive exercised options to buy US$273k worth of stock.

Acumen Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Acumen Pharmaceuticals, Inc. Publishes Phase 1 Trial Design and Clinical Development Plan for ACU193

Acumen Pharmaceuticals, Inc. Acu193, an Anti-Amyloid Beta Oligomer Antibody, Granted Fda Fast Track Designation for Alzheimer's Disease

Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans

Price target increased to US$16.00

Acumen Pharma at 11-month high on rivals’ Alzheimer’s data

Acumen Pharmaceuticals, Inc. Announces Resignation of Dr. Jeffrey Sevigny to Its Board of Directors

Acumen Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Acumen Pharmaceuticals initiated at buy at H.C. Wainwright on Alzheimer's candidate

Acumen Pharmaceuticals, Inc.(NasdaqGS:ABOS) dropped from Russell 2500 Value Index

Acumen Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 16, 2022

We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth

Full year 2021 earnings released

Acumen Pharmaceuticals, Inc. Announces Management Changes

We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate

Third quarter 2021 earnings released: US$0.10 loss per share

Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans

Acumen Pharmaceuticals, Inc. has completed an IPO in the amount of $159.999984 million.

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken